首站-论文投稿智能助手
典型文献
Screening and identification of HTNVpv entry inhibitors with high-throughput pseudovirus-based chemiluminescence
文献摘要:
Hantaviruses,such as Hantaan virus(HTNV)and Seoul virus,are the causative agents of Hantavirus cardiopul-monary syndrome(HCPS)and hemorrhagic fever with renal syndrome(HFRS),and are important zoonotic pathogens.China has the highest incidence of HFRS,which is mainly caused by HTNV and Seoul virus.No approved antiviral drugs are available for these hantaviral diseases.Here,a chemiluminescence-based high-throughput-screening(HTS)assay was developed and used to screen HTNV pseudovirus(HTNVpv)inhibitors in a library of 1813 approved drugs and 556 small-molecule compounds from traditional Chinese medicine sources.We identified six compounds with in vitro anti-HTNVpv activities in the low-micromolar range(EC50 values of 0.1-2.2 μmol/L;selectivity index of 40-900).Among the six selected compounds,cepharanthine not only showed good anti-HTNVpv activity in vitro but also inhibited HTNVpv-fluc infection in Balb/c mice 5 h after infection by 94%(180 mg/kg/d,P<0.01),93%(90 mg/kg/d,P<0.01),or 92%(45 mg/kg/d,P<0.01),respectively,in a bioluminescent imaging mouse model.A time-of-addition analysis suggested that the antiviral mechanism of cepharanthine involves the membrane fusion and entry phases.Overall,we have established a HTS method for antiviral drugs screening,and shown that cepharanthine is a candidate for HCPS and HFRS therapy.These findings may offer a starting point for the treatment of patients infected with hantaviruses.
文献关键词:
作者姓名:
Xiaojing Wen;Li Zhang;Qiang Liu;Xinyue Xiao;Weijin Huang;Youchun Wang
作者机构:
Division of HIV/AIDS and Sex-transmitted Virus Vaccines,Institute for Biological Product Control,National Institutes for Food and Drug Control(NIFDC)and WHO Collaborating Center for Standardization and Evaluation of Biologicals,Beijing 102629,China;Department of Microbiological Laboratory Technology,School of Public Health,Shandong University,Jinan 250012,China;Institute for Reference Standards and Standardization,National Institutes for Food and Drug Control,Beijing 102629,China
文献出处:
引用格式:
[1]Xiaojing Wen;Li Zhang;Qiang Liu;Xinyue Xiao;Weijin Huang;Youchun Wang-.Screening and identification of HTNVpv entry inhibitors with high-throughput pseudovirus-based chemiluminescence)[J].中国病毒学,2022(04):531-537
A类:
HTNVpv,Hantaviruses,cardiopul,hantaviral,micromolar,bioluminescent,hantaviruses
B类:
Screening,identification,entry,inhibitors,throughput,pseudovirus,chemiluminescence,such,Hantaan,Seoul,are,causative,agents,monary,syndrome,HCPS,hemorrhagic,fever,renal,HFRS,important,zoonotic,pathogens,China,highest,incidence,which,mainly,caused,by,No,approved,antiviral,drugs,available,these,diseases,Here,screening,HTS,assay,was,developed,library,small,molecule,compounds,from,traditional,Chinese,medicine,sources,We,identified,six,vitro,activities,low,range,EC50,values,selectivity,Among,selected,cepharanthine,only,showed,good,activity,but,also,inhibited,fluc,infection,Balb,mice,after,respectively,imaging,mouse,model,addition,analysis,suggested,that,mechanism,involves,membrane,fusion,phases,Overall,have,established,method,shown,candidate,therapy,These,findings,may,offer,starting,point,treatment,patients,infected
AB值:
0.518084
相似文献
Systematic screening reveals synergistic interactions that overcome MAPK inhibitor resistance in cancer cells
Yu Yu;Minzhen Tao;Libin Xu;Lei Cao;Baoyu Le;Na An;Jilin Dong;Yajie Xu;Baoxing Yang;Wei Li;Bing Liu;Qiong Wu;Yinying Lu;Zhen Xie;Xiaohua Lian-Department of Cell Biology,Basic Medical College,Army Medical University(Third Military Medical University),Chongqing 400038,China;MOE Key Laboratory of Bioinformatics and Bioinformatics Division,Center for Synthetic and System Biology,Department of Automation,Beijing National Research Center for Information Science and Technology,Tsinghua University,Beijing 100084,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Thoracic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China;Beijing Syngentech Co.,Ltd,Beijing 102206,China;School of Life Sciences,Tsinghua University,Beijing 100084,China;The Comprehensive Liver Cancer Center,The 5th Medical Center of PLA General Hospital,Beijing 100039,China
Rapid screening of SARS-CoV-2 inhibitors via ratiometric fluorescence of RBD—ACE2 complexes in living cells by competitive binding
Lu Miao;Wei Zhou;Chunyu Yan;Yuebin Zhang;Qinglong Qiao;Xuelian Zhou;Yingzhu Chen;Guangying Wang;Zhen-dong Guo;Jun Liu;Hailong Piao;Xia Pan;Mengxue Yan;Weijie Zhao;Guohui Li;Yueqing Li;Zhaochao Xu-CAS Key Laboratory of Separation Science for Analytical Chemistry,Dalian Institute of Chemical Physics,Chinese Academy of Sciences,Dalian 116023,China;State Key Laboratory of Molecular Reaction Dynamics,Dalian Institute of Chemical Physics,Chinese Academy of Sciences,Dalian 116023,China;Institute of Military Veterinary Science,The Academy of Military Medical Science of PLA,Changchun 130000,China;State Key Laboratory of Fine Chemicals,Department of Pharmaceutical Sciences,School of Chemical Engineering,Dalian University of Technology,Dalian 116024,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19
Yang Yi;Meng Zhang;Heng Xue;Rong Yu;Yang-Oujie Bao;Yi Kuang;Yue Chai;Wen Ma;Jing Wang;Xiaomeng Shi;Wenzhe Li;Wei Hong;Junhua Li;Elishiba Muturi;Hongping Wei;Joachim Wlodarz;Szczepan Roszak;Xue Qiao;Hang Yang;Min Ye-State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;CAS Key Laboratory of Special Pathogens and Biosafety,Center for Biosafety Mega-Science,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,China;University of Chinese Academy of Sciences,Beijing 100049,China;Faculty of Science and Technology,University of Silesia,Katowice 40-007,Poland;Department of Physical and Quantum Chemistry,Faculty of Chemistry,Wroclaw University of Science and Technology,Wroclaw 50-370,Poland
Chalcone derivatives ameliorate lipopolysaccharide-induced acute lung injury and inflammation by targeting MD2
Ya-li Zhang;Wen-xin Zhang;Jue-qian Yan;Ye-lin Tang;Wen-jing Jia;Zheng-wei Xu;Ming-jiang Xu;Nipon Chattipakorn;Yi Wang;Jian-peng Feng;Zhi-guo Liu;Guang Liang-Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325035,China;Key Laboratory of Molecular Pharmacology and Drug Evaluation(Yantai University),Ministry of Education,Yantai University,Yantai 264005,China;School of Pharmaceutical Sciences,Hangzhou Medical College,Hangzhou 311399,China;Zhuji Biomedicine Institute,School of Pharmaceutical Sciences,Wenzhou Medical University,Zhuji 311800,China;Cardiac Electrophysiology Research and Training Center,Faculty of Medicine,Chiang Mai University,Chiang Mai 50200,Thailand;Wenzhou Institute,University of Chinese Academy of Sciences,Wenzhou 325001,China
Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
Yi Wang;Sui Fang;Yan Wu;Xi Cheng;Lei-ke Zhang;Xu-rui Shen;Shuang-qu Li;Jian-rong Xu;Wei-juan Shang;Zhao-bing Gao;Bing-qing Xia-CAS Key Laboratory of Receptor Research,Stake Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430071,China;Academy of Integrative Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of Pharmacology and Chemical Biology,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Zhongshan Institute of Drug Discovery,Institution for Drug Discovery Innovation,Chinese Academy of Science,Zhongshan 528400,China
Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis
Ying Dong;Bi-xi Tang;Qi Wang;Li-wei Zhou;Cong Li;Xuan Zhang;Dan-dan Sun;Xin Sun;Xue-mei Zhang;Bing Xiong;Jia Li;Hong Shi;Dan-qi Chen;Yi Zang-State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Department of Pharmacology,School of Pharmacy,Fudan University,Shanghai 201203,China;Department of Medicinal Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Center for Supramolecular Chemistry and Catalysis and Department of Chemistry,College of Sciences,Shanghai University,Shanghai 200444,China;Schoolof Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing 210023,China;Schoolof Pharmacy,Henan University,Kaifeng 475004,China;Open Studio for Druggability Research of Marine Natural Products,Pilot National Laboratory for Marine Science and Technology(Qingdao),Qingdao 266237,China;School of Pharmaceutical Science and Technology,Hangzhou Institute for Advanced Study,UCAS,Hangzhou 310024,China;Department of Anesthesiology of Shanghai Pulmonary Hospital,School of medicine,Tongji University,Shanghai 200433,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Celastrol suppresses the growth of vestibular schwannoma in mice by promoting the degradation of β-catenin
Na Hui Kim;Minji Kwon;Jiwoo Jung;Hyo Byeong Chae;Jiwoo Lee;Yeo-Jun Yoon;In Seok Moon;Ho K.Lee;Wan Namkung;Konstantina M.Stankovic;Se A.Lee;Jong Dae Lee;Sin-Aye Park-Department of ICT Environmental Health System,Graduate School,Soonchunhyang University,Asan-si 31538,Republic of Korea;Department of Biomedical Laboratory Science,College of Medical Sciences,Soonchunhyang University,Asan-si 31538,Republic of Korea;Department of Otorhinolaryngology,Yonsei University,College of Medicine,Seoul 03722,Republic of Korea;Colllege of Pharmacy and Yonsei Institute of Pharmaceutical Sciences,Yonsei University,Yeonsu-gu,Incheon 21983,Republic of Korea;Department of Otolaryngology-Head and Neck Surgery,Stanford University School of Medicine,Stanford,CA 94305,USA;Department of Otorhinolaryngology-Head and Neck Surgery,Soonchunhyang University Bucheon Hospital,Bucheon 14584,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。